This application is related to commonly owned U.S. Pat. No. 6,366,813, filed Jun. 25, 1999 and U.S. Pat. No. 6,819,956, filed Nov. 11, 2001.
This application is also related to commonly owned U.S. patent application Ser. Nos. 11/321,897 and 11/322,150, both filed Dec. 28, 2005
The present invention relates generally to reducing artifacts in a sampled physiological signal from a subject. More specifically, the present invention relates to methods and systems for delivering stimulation in separate epochs of time from data acquisition epochs of time.
Closed loop neurological stimulation systems that acquire physiological signals from a subject and stimulate a subject can produce stimulation-induced artifact signals when the acquisition of the physiological signal from the subject and stimulation of the subject occur substantially at the same time.
For example, electroencephalographic (EEG) signals acquired from subjects are small in amplitude and relatively low in frequency. Scalp EEG signals, for example, have amplitudes on the order of about 10 uV to about 100 uV and have frequency content in the range of about 0.1 to about 70 Hz. Electrocorticography (ECoG) is the practice of recording signals directly from the surface of the cerebral cortex. ECoG signals are larger, in the range of about 10 uV to about 1000 uV, and depending on the size and geometry of the measuring electrode, which may vary from a disk contact several mm in diameter to a needle-like micro-electrode with dimensions on the orders of microns, these signals may contain useful information at frequencies from 0.01 Hz up to up to several hundred Hz. In practice, the term EEG or intracranial EEG is often used in place of the term ECoG; for simplicity we will use the term “EEG” throughout the remainder of this document to encompass both intracranial EEG and scalp EEG.
Electrical stimulation signals used to stimulate nerve cells are typically similar in frequency to EEG signals but can be much larger in amplitude. Typical stimulation frequencies, or pulse repetition frequencies, range from about 1 Hz to about 1000 Hz. Stimulation pulse widths are typically on the order of about 50 us to about 500 us. Pulse shapes are typically rectangular rather than smoothed or sinusoidal, and therefore generate significant amount of energy at harmonics of the pulse repetition frequency. Typical stimulation waveform amplitudes may be in the range of about 1 V to about 10 V, and when coupled to stimulating electrodes with typical electrode impedances of about 500 Ohms to about 2000 Ohms, this leads to stimulation current amplitudes of between about 0.5 mA and about 20 mA. In order to avoid damage to neural tissue or to the stimulating electrodes, the charge per stimulation pulse should be limited to below about 100 uC to about 200 uC per square cm of electrode area.
A stimulation signal may cause artifact when sensed at substantially the same time as a physiological signal because the electrical stimulation signal can be substantially larger and in substantially the same frequency band as the physiological signal (e.g., an EEG signal).
Stimulation-induced artifact can be reduced by filtering out the artifact signal. Some existing technologies may also synchronize the timing of the filtering process with the timing of the stimulation signal in order to reduce stimulation-induced artifact. These systems, however, do not control the time at which the signal acquisition and stimulation occur, but rather rely on filtering out the artifact signal after it has already been acquired. In addition, some systems simply disable the detection device while stimulation occurs.
There remains a need for a neurological stimulation system which acquires physiological signals from a subject and stimulates the subject to reduce the amount of stimulation-induced artifact sensed by the system.
One aspect of the invention is a system to reduce artifact in a signal acquired from a subject. The system includes a sensing assembly adapted to acquire a signal from a subject indicative of the subject's brain activity, a stimulation assembly adapted to stimulate one or more neurons of the subject, and a timing controller programmed to control the time at which the sensing assembly acquires the signal to be substantially different than when the stimulation assembly stimulates the subject.
In some embodiments of the system the timing controller is programmed to control the time at which the sensing assembly acquires the signal to be multiple discrete acquisition times and to control the time at which the stimulation assembly stimulates the one or more neurons to be multiple discrete stimulation times. The timing controller can be programmed to control the sensing assembly to acquire the signal in between the stimulation assembly stimulating the one or more neurons. In some embodiments the multiple discrete acquisition times and multiple discrete stimulation times each occur in a regular pattern. In some embodiments the acquisition times and the stimulation times provide epochs of time between the acquisition times and stimulation times in which no acquisition or stimulation occurs.
In some embodiments the multiple discrete acquisition times are about 0.25 seconds to about 5 minutes. In some embodiments the multiple discrete acquisition times are about 5 seconds.
In some embodiments the multiple discrete stimulation times are about 0.5 seconds to about 5 minutes. In some embodiments the multiple discrete acquisition times are about 20 seconds.
In some embodiments the sensing assembly and the stimulation assembly each comprise an electrode array. The same electrode array can be used to stimulate the one or more neurons and acquire the signal from the subject. In some embodiments the stimulation assembly comprises an electrode array adapted to be coupled to a peripheral nerve. In some embodiments the peripheral nerve is a vagus nerve.
In some embodiments the signal is an EEG signal from the subject.
In some embodiments the system further comprises a control assembly adapted to adjust the multiple discrete acquisition times and the multiple discrete stimulation times. The control assembly can be in communication with a device external to the subject wherein the device is adapted to allow adjustment of the stimulation and acquisition times. In some embodiments the control assembly is adapted to dynamically adjust the stimulation or acquisition times.
In some embodiments of the system the subject's brain activity is analyzed to predict an onset of a seizure.
In some embodiments the system also includes a signal processor in communication with the sensing assembly adapted to process the signal to estimate an epileptic neural state. The signal processor can comprise an observer algorithm operative when the sensing assembly is acquiring the signal. In some embodiments the observer algorithm comprises one or more feature extractors and a classifier.
Another aspect of the invention is a method of reducing artifact in a signal acquired from a subject. The method comprises acquiring a signal from a subject indicative of the subject's brain activity, stimulating the subject, and controlling the time at which the acquiring the signal occurs to be substantially different than the stimulating the subject.
In some embodiments the acquiring comprises acquiring the signal at multiple discrete acquisition times and the stimulating comprises stimulating the one or more neurons at multiple discrete stimulation times. The acquiring the signals can occur between the stimulating the subject. In some embodiments the acquiring and stimulating each occur in a regular pattern.
In some embodiments the multiple discrete acquisition times are about 0.25 seconds to about 5 minutes. In some embodiments the multiple discrete acquisition times are about 5 seconds.
In some embodiments the multiple discrete stimulation times are about 0.5 seconds to about 5 minutes. In some embodiments the multiple discrete stimulation times are about 20 seconds.
In some embodiments the acquiring comprises acquiring an EEG signal from the subject. In some embodiments the stimulating comprises stimulating a peripheral nerve such as a vagus nerve.
In some embodiments the method further comprises adjusting the multiple discrete acquisition times and/or the multiple discrete stimulation times.
In some embodiments the subject's brain activity is processed to measure the subject's susceptibility to a seizure.
In some embodiments the method further comprises processing the signal to estimate an epileptic neural state.
Another aspect of the invention is a method of managing seizures. The method comprises acquiring an EEG signal from a subject during multiple discrete acquisition times occurring in a regular pattern, stimulating one or more neurons of the subject during multiple discrete stimulation times occurring in a regular pattern, and controlling the times at which the acquiring the EEG signal occurs to be substantially different than the stimulating the one or more neurons of the subject.
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
The systems of the present invention generally reduce artifact in a signal, e.g., an electrical signal, acquired from a subject. In particular, the system can reduce stimulation-induced artifact sensed with a neurological stimulation system that is at least partially implanted in a subject. One aspect of the invention is a system that comprises a sensing assembly adapted to acquire a signal from a subject that contains data that is indicative of the subject's brain activity state or neural state, a stimulation assembly adapted to stimulate one or more neurons of a nervous system component of the subject, and a timing controller programmed to control the time of acquiring the signal(s) from the subject and delivering electrical stimulation to the subject.
The present invention can reduce artifact in the acquired signal by controlling the time at which the signal is acquired from the subject to be substantially different than the time at which the subject is stimulated. Controlling the timing of the signal acquisition and stimulation can reduce the amount of stimulation signal that is sensed by the sensing assembly, thus reducing artifact signals. Furthermore, as data acquisition and stimulating requires the use of power, which may be limited in an implantable neurological stimulation system, controlling the sensing assembly and stimulation assembly to acquire a signal and stimulate at specific times, rather than sensing and stimulating continuously, allows for a more efficient use of the system's power supply.
The methods of the present invention are applicable to closed-loop control systems for controlling a subject's state, closed-loop detection and prediction systems that are used to detect and/or predict the onset of neurological events, and other closed-loop systems which acquire data and deliver a neuromodulation signal to the subject. Each of such systems will typically include one or more algorithms for analyzing signals from the subject and/or determining the subject's response to the analyzed signals. Such algorithms will be referred to herein collectively as an “observer algorithm.”
While the remaining discussion focuses on closed-loop control of seizures and detecting and/or predicting an onset of seizures, the present invention may be equally applicable to monitoring and treatment of other neurological and non-neurological conditions. For example, some other conditions that may be treated using the systems of the present invention include, but is not limited to, Alzheimer' disease, Parkinson's disease, migraine headaches, sleep apnea, Huntington's disease, hemiballism, choreoathetosis, dystonia, akinesia, bradykinesia, restless legs syndrome, other movement disorder, dementia, depression, mania, bipolar disorder, other affective disorder, motility disorders, anxiety disorder, phobia disorder, borderline personality disorder, schizophrenia, multiple personality disorder, and other psychiatric disorder, Parkinsonism, rigidity, or hyperkinesias, substance abuse, attention deficit hyperactivity disorder, impaired control of aggression, impaired control of sexual behavior, or the like.
While the electrode arrays may be implanted anywhere within the subject's body, preferred electrode arrays include intracranial or extracranial EEG electrode arrays. The EEG electrode arrays can be adapted to be placed on the subject's head, implanted under the skin, screwed into the skull, or implanted intracranially. For example, in minimally invasive embodiments the electrode array can be implanted beneath at least one layer of the scalp, above the subject's cranium/calvarium, and over one or more target area of the subject's brain. The electrode array may be implanted between any of the layers of the scalp. For example, the electrode array may be positioned between the skin and the connective tissue, between the connective tissue and the epicranial aponeurosis/galea aponeurotica, between the epicranial aponeurosis/galea aponeurotica and the loose aerolar tissue, between the loose aerolar tissue and the pericranium, and/or between the pericranium and the calvarium. In some configurations, it may be useful to implant different electrode arrays between different layers of the scalp.
In more invasive embodiments the electrode array of the sensing assembly includes an intracranial (IC) recording electrode array (e.g., epidural, subdural, depth electrodes, etc.) or a bone screw array which samples intracranial neural signals, including but not limited to cortical, white matter, and deep brain signals. Neural activity to be sensed includes but is not limited to that found in the primary motor cortex, premotor cortex, supplementary motor cortex, somatosensory cortex, white matter tracts associated with these cortical areas, the globus pallidus internal segment, the globus pallidus external segment, the caudate, the putamen, and other cortical and subcortical areas.
The EEG electrode arrays used with the system 2 may include any number of electrodes, and can be placed at a variety of locations in or on the subject such that an EEG signal can be acquired from the subject. The EEG electrode array typically includes between about 8 electrodes and 64 electrodes, but may have more or less, as desired. Some useful electrode arrays include a 1×8 electrode strip, a 2×4 electrode grid, a 3×3 grid array, a 1×8 depth electrode array, an array of bone screws, sphenoidal electrode array, and a nerve cuff electrode array, but many other configurations and types of electrodes may also be useful with the system.
While EEG electrode arrays are one currently preferred embodiment, other types of electrode arrays may also be used in addition to or as an alternative to the EEG electrode arrays. For example, the electrode arrays may include any of the following types of electrodes, either alone or in combination with each other, an electromyography (EMG) array for acquiring EMG signals, an accelerometer array for acquiring acceleration signals, an acoustic transducer array, a peripheral nerve electrode array (e.g., vagus nerve), a cranial nerve electrode array (e.g., trigeminal nerve) or other biological sensors or electrodes for monitoring blood pressure, pulse oximetry, temperature of the brain or other portion of the subject, blood flow measurements in the brain or other parts of the body, ECG/EKG, heart rate signals and/or change in heart rate signals, respiratory rate signals and/or change in respiratory rate signals, chemical concentrations of neuro transmitters, chemical concentrations of medications, pH in the blood or other portions of the body, other vital signs, other physiological or biochemical parameters of the subject's body, or the like.
For example, as noted above, another type of sensing electrode array that may be used with the system is a peripheral nerve electrode array which may be used to acquire peripheral neural signals, including but not limited to efferent and afferent axonal signals from a vagus nerve. The single or plurality of individual peripheral nerve electrode arrays which comprise peripheral nerve electrode array may be implanted in any number of locations throughout the subject. Such peripheral nerve electrode arrays may also be used to deliver a stimulation output signal to the subject. Additional electrode arrays which can also be included in the sensing assembly can be found in commonly owned U.S. Pat. No. 6,366,813, which issued Apr. 2, 2002.
Data acquisition and stimulation may be performed using different sets of electrode arrays, the same sets of electrode arrays, or a mixed set of electrodes within the arrays. For example,
In other configurations it may be desirable to use one electrode array 9 (e.g., electrodes A-H) to sense signals and to use electrode array 11 (e.g., electrodes I-P) to deliver stimulation to the subject. In yet other configurations it may be desirable to use some or all of the electrodes on arrays 9, 11 to sense and to use some or all of the electrodes to deliver stimulation. For example, it may be desirable to use a mixed set of electrodes to sense and stimulate. For example, electrodes A-H of array 9 may be used to sense signals and electrodes B-C-F-G may be used to deliver electrical stimulation. Similarly, electrodes I-M of array 11 may be used to sense signals and electrodes L-P may be used to deliver electrical stimulation.
The systems of the present invention typically include one or more implantable devices or components and one or more external devices or components. However, in other embodiments, the entire system may be implantable within the subject. Any number of the system components can be adapted to be implantable or external to the subject.
The signals sensed by sensing assembly 6 are typically reflective of the subject's brain activity state and/or neural state. Analysis of the brain activity state by the observer algorithm may indicate that the subject is in an inter-ictal state (e.g., a normal state) in which the subject has a low susceptibility to a seizure, a pro-ictal state (e.g., a state that has an increased susceptibility to a seizure), a pre-ictal state (e.g., a state that indicates that a seizure is imminent), an ictal state (e.g., a state in which a seizure is already occurring) or a post-ictal state (e.g., a seizure has ended). As will be described in more detail below, it may be desirable to use such determinations of brain state to modify one or more parameters of the duty cycling, stimulation parameters and/or sensing parameters.
System 2 may be used with closed-loop control systems that are adapted to control the subject's neural state so as to substantially prevent the subject from entering a neural state in which the subject has an elevated susceptibility to a seizure. Delivery of electrical stimulation may be used to maintain the subject's neural state in a state that is at low susceptibility or in cases in which the subject has entered a neural state that has an elevated susceptibility to a seizure, to drive the subject's neural state from the elevated susceptibility to a seizure back down to a neural state that is at a low susceptibility to a seizure.
In order to provide stimulation and sensing of the subject's state, preferred embodiments of the system 2 comprise a timing controller 4 which may be programmed to control the time at which the sensing assembly 6 acquires the signal to be substantially different than the time when the stimulation assembly 8 stimulates the subject. In preferred embodiments the timing controller 4 is in communication with both the sensing assembly and the stimulating assembly, as shown in
In some embodiments the timing controller 4 is programmed to control the time at which the sensing assembly 6 acquires the signal to be multiple discrete acquisition times and/or to control the time at which the stimulation assembly 8 stimulates the nervous system component to be multiple discrete stimulation times. The multiple discrete acquisition and stimulation times can be of any number and may be of any duration.
In some embodiments the timing controller can be programmed to control either the multiple discrete acquisition epochs and/or the multiple discrete stimulation epochs to occur in a regular pattern or adaptively. For example, the multiple discrete acquisition and or stimulation times can occur on a regular cycle or Period, as shown in
Some subjects are more prone to having seizures at specific times of day. Consequently, the timing controller may be programmed to automatically adjust the acquisition epochs and stimulation epochs based on time of day. For example, if the subject was known to have a particular vulnerability upon awakening from sleep, the timing controller could be configured to increase a duty cycle of sensing epochs in the morning hours.
In addition to the modification of the parameters within the epochs, the Period of the stimulation signal (as shown in
The scheduling of acquisition epochs and/or the stimulation epochs may be based on a duty cycle. Duty cycle as used herein refers to the ratio of the duration of the event in a given Period to the Period. As shown in
The lengths of the data acquisition epochs, stimulation epochs and Period may vary from subject to subject and may vary based on the particular disorder being treated. For example, for treating epilepsy, the acquisition epoch is typically between about 0.25 seconds to about 5 minutes, preferably between about 1 second to about 30 seconds, and more preferably about 5 seconds. The stimulation epochs are typically between about 0.5 seconds to about 5 minutes, preferably between about 1 seconds and about 30 seconds, and most preferably about 20 seconds. As noted above, in some embodiments it may be desirable to have epochs of time between the data acquisition and stimulation epochs in which the system does not acquire signal from or deliver stimulation to the subject. The duration of these epochs of time is typically between 0.25 seconds and about 10 seconds, preferably between about 1 seconds and about 5 seconds, and most preferably about 4 seconds, but the length of such epochs may depend on the recovery of electrodes from voltage offsets caused by stimulation activity and/or by the acquisition and/or stimulation time programmed into the timing controller.
The duty cycling methods described above are equally applicable to systems whose observer algorithms are adapted for seizure prediction and seizure detection. In the seizure prediction/detection systems, neuromodulation (e.g., electrical stimulation) may only be delivered to the subject when it is determined that the subject has an elevated susceptibility for a seizure (e.g., a seizure is predicted). As shown in
The observer algorithms of the devices may be adapted to continue to analyze the discontinuous epochs of data to estimate the subject's susceptibility to a seizure while stimulation is initiated. By duty cycling the data acquisition and stimulation epochs, the seizure prediction and seizure detection devices are able to analyze the brain activity signals determine if the stimulation is effective in mitigating the subject's susceptibility to a seizure, while still reducing artifact in the sensed signals. While not shown in
If however, the observer algorithm determines that the stimulation epochs have not reduced the subject's susceptibility for a seizure, a number of different actions could be carried out. First, the stimulation epochs may be continued using the same stimulation parameters and duty cycled with the data acquisition epochs. Second, one or more parameters of the duty cycling may be varied. For example, it may be useful to increase a duration of the stimulation epochs and/or reduce a duration of the data acquisition epochs and/or the epochs between the stimulation epoch and data acquisition epochs. Third, one or more parameters of the stimulation epoch may be automatically adaptively varied in an attempt to find a combination of parameters that are effective for the particular subject. If a certain combination of stimulation parameters are able to affect the subject's brain activity state better than other combinations of parameters, such parameters may be stored in memory and used for subsequent stimulation epochs.
The observer algorithm may be embodied in a device that is implanted in the subject, embodied in a device that is external to the subject, or in separate modules in both the implanted unit and external device. The observer algorithm may be used to analyze the subject's brain activity so as to determine the appropriate control signal, determine the subject's susceptibility to a seizure, predict/detect a seizure, and facilitate delivery of an appropriate electrical stimulation to the subject.
The electrode arrays 9, 11 will be configured to sample the brain activity of the groups of neurons in the immediate vicinity of the electrode arrays 9, 11. The electrode arrays 9, 11 are electrically joined via cables 26 to the implanted unit 24. In one embodiment, the electrode arrays 9, 11 are implanted intracranially and the cables 26 are tunneled beneath the skin through the neck to the implanted unit 24 that is implanted in a subclavicular cavity of the subject. In alternative embodiments, the cables 26 and unit 24 may be attached to the subject externally.
In one embodiment, the implanted unit 24 is configured to facilitate the sampling of signals from the electrodes 9, 11. Sampling of brain activity is typically carried out at a rate above about 200 Hz, and preferably between about 200 Hz and about 1000 Hz, and most preferably at about 400 Hz. The sampling rates could be higher or lower, depending on the specific conditions being monitored, the subject, and other factors. Each sample of the subject's brain activity is typically encoded using between about 8 bits per sample and about 24 bits per sample, and preferably about 16 bits per sample.
In alternative embodiments, the implanted unit 24 may be configured to monitor the signals on a non-continuous basis. In such embodiments, signals may be monitored periodically or aperiodically.
The external data analysis/collection device 22 is preferably carried external to the body of the subject. The external device 22 can be a computer system, such as, e.g., a personal computer, handheld device, physician programmer, or the like. The external device 22 receives and stores signals, including EEG signals and possibly other physiological signals, from the implanted unit 24. Communication between the external data device 22 and the implanted unit 24 may be carried out through wireless communication, such as an infrared link, ultrasonic link, inductive link, radiofrequency link, or the like. The wireless communication link between the external data device 22 and the implanted unit 24 is typically a two-way communication link for transmitting data but could be a one-way communication link. For example, the external device and implanted unit could include both a two-way inductive link (short distance magnetic loop coupling) and a one-way RF link for sending alerts to the subject.
In alternative embodiments, it may be desirable to have a direct communications link from the external data device 22 to the implanted unit 24, such as, for example, via an interface device positioned below the subject's skin. The interface (not shown) may take the form of an adhesively or magnetically attached transducer that would enable power to be continuously delivered to the implanted unit 24 and would provide for relatively higher rates of data transmission. Error detection and correction methods may be used to help insure the integrity of transmitted data. If desired, the wireless data signals can be encrypted prior to transmission to the external data device 22.
The implanted unit 24 may optionally comprise electronic component systems as depicted schematically in
The amplifiers may be one or more single amplifiers or a multi-channel amplifiers depending upon the number of electrodes with which it interfaces. In some embodiments, the amplifiers are physically located in the same enclosure as the filters that is, in a single signal conditioner. The amplifiers may also be located separately from the filters. For example, the amplifier may be affixed to or situated adjacent to an associated electrode array. This arrangement facilitates the pre-amplification of the associated signals generated by the associated electrode arrays, which increases the signal-to-noise ratio of the acquired signals. The amplifiers may be any known voltage amplifier now or later developed suitable for amplifying the particular signals generated by an associated electrode or electrode array.
The amplified signal may then be passed to an associated filter. The filter can be physically separate from or incorporated into sensing assembly. The filter may be a low pass filter. The low pass filter typically has a cut-off frequency of 1000 Hz, preferably of 300 Hz, and most preferably of 150 Hz. In addition to or as an alternative to the low-pass filter, the device may include a notch filter to remove, for example, 50 or 60 Hz noise, or other types of filters appropriate for the type of signals acquired by an associated electrode arrays.
In preferred embodiments the sensing assembly also includes a signal processor or other dedicated hardware for further processing the conditioned signal. The signal processor can be implemented in, e.g., a fast microprocessor, a DSP (digital signal processor) chip, ASIC, or as analog circuitry. The signal processor (and any of the other signal processors described herein) may include multiple cores so as to improve processing throughput, while further reducing power consumption. The signal processor can include a separate signal processor for each conditioned signal which can be input if a plurality of electrodes acquire signal from the subject. Such signal processors may be used to filter, extract features from, transform, generate statistics for, or encrypt the sampled signals.
A memory module 38 may be provided for storage of some or all of the sampled signals prior to transmission via a transmit/receive sub-system 30 and antenna 40 to the external data device 22. For example, the memory module 40 may be used as a buffer to temporarily store the conditioned signals from the electrode arrays 9, 11 if there are problems with transmitting data to the external data device 22, such as may occur if the external data device 22 experiences power problems or is out of range of the communications system. The external data device 22 can be configured to communicate a warning signal to the subject in the case of data transmission problems to inform the subject and allow him or her to correct the problem. Memory module 38 may also be used to permanently store a portion or all of the sampled EEG signals, if desired.
The implanted unit 24 may optionally comprise dedicated circuitry of a digital or analog or combined digital/analog nature, ASIC, DSP and/or a fast microprocessor, referred to herein collectively as “processor” 42, for further processing the signals prior to transmission to the external data device 22. In some embodiments, the processor 42 may execute one or more observer algorithms such as, neurological event prediction or detection algorithms, seizure prediction algorithms, seizure detection algorithms, or portions of such algorithms. For example, in some configurations, the processor 42 may run one or more feature extractors that extract features from the EEG signal that are relevant to the purpose of monitoring. Thus, if the system is being used for diagnosing or monitoring epileptic subjects, the extracted features (either alone or in combination with other features) may be indicative or predictive of a seizure. Once the feature(s) are extracted, the processor 42 may transmit the extracted feature(s) to the external data device 22 and/or store the extracted feature(s) in memory 38. Because the transmission of the extracted features is likely to include less data than the EEG signal itself, such a configuration will likely reduce the bandwidth requirements for the communication link between the implanted unit 24 and the external data device 22.
The received data may thereafter be stored in memory 54, such as a hard drive, RAM, EEPROM, flash memory, or the like and/or processed by a microprocessor, ASIC, DSP, or other dedicated circuitry of a digital or analog or combined digital/analog nature, referred to herein collectively as a “processor” 56. Processor 56 may be configured to request that the implanted unit 24 perform various checks or calibrations prior to signal recording and/or at specified times to ensure the proper functioning of the system.
Data may be transmitted from memory 54 to processor 56 where the data may optionally undergo additional processing. For example, if the EEG data is encrypted, it may be decrypted. The processor 56 may also comprise one or more filters that filter out high-frequency artifacts (e.g., muscle movement artifacts, eye-blink artifacts, chewing, etc.) so as to prevent contamination of the high frequency components of the sampled EEG signals. In some embodiments, the processor 56 may process the EEG data to detect seizures, predict the onset of a future seizure, generate metrics/measurements of seizure activity, or the like as described below.
External data device 22 will typically include a user interface 60 for displaying outputs to the subject and for receiving inputs from the subject. The user interface will typically comprise outputs such as auditory devices (e.g., speakers) visual devices (e.g., LCD display), tactile devices (e.g., vibratory mechanisms), or the like, and inputs, such as a plurality of buttons, a touch screen, and/or a scroll wheel.
The user interface may be adapted to allow the subject to indicate and record certain events. For example, the subject may indicate that medication has been taken, the dosage, the type of medication, meal intake, sleep, drowsiness, occurrence of an aura, occurrence of a seizure, or the like. Such inputs may be used in conjunction with the recorded data to improve the off-line or on-line analysis of the subject's condition and determine the efficacy of the medications taken by the subject.
The LCD display may be used to output a variety of different communications to the subject including, status of the device (e.g., memory capacity remaining), battery state of one or more components of system, whether or not the external data device 22 is within communication range of the implanted unit 24, a warning (e.g., a seizure warning), a prediction (e.g., a seizure prediction), a recommendation (e.g., “take medicine”), or the like. Of course, it may be desirable to provide an audio output or vibratory output to the subject in addition to or as an alternative to the visual display on the LCD.
External data device 22 may also include a power source 62 or other conventional power supply that is in communication with at least one other component of external data device 22. The power source 62 may be rechargeable. If the power source 62 is rechargeable, the power source may optionally have an interface for communication with a charger 64. External data device 22 may also include a communication interface 66 for coupling to a remote computer 68 (e.g., a physician's computer workstation). While not shown in
In a preferred embodiment, most or all of the processing of the signals received by the implanted unit 24 is done in an external data device 22 that is external to the subject's body. In such embodiments, the implanted unit 24 would receive the signals from subject and may or may not pre-process the signals and transmit some or all of the measured signals transcutaneously to an external data device 22, where the observer algorithm processes the EEG data. Advantageously, such embodiments reduce the amount of computational processing power that needs to be implanted in the subject, thus potentially reducing power consumption and increasing battery life. Furthermore, by having the processing external to the subject, the judgment or decision making components of the system may be more easily reprogrammed or custom tailored to the subject without having to reprogram the implanted unit 24.
In alternative embodiments, the observer algorithms disclosed herein and treatment algorithms responsive to the predictive algorithms may be embodied in a device that is implanted in the subject's body or the algorithm may be modular and some modules may be implanted in the subject's body and other modules may be external to the subject's body. For example, in one embodiment the observer algorithm may be stored in and processed by the implanted unit 24. A treatment algorithm, in contrast, may be processed in a processor that is embodied in an external data device 22 external to the subject's body. In such embodiments, the subject's propensity for seizure characterization (or whatever output is generated by the observer algorithm) is transmitted to the external device 22, and the processor performs any remaining processing to generate and display the output from the observer algorithm and communicate this to the subject. Such embodiments have the benefit of sharing processing power, while reducing the communications demands on the implanted unit 24. Furthermore, because the treatment algorithm is external to the subject, updating or reprogramming the treatment algorithm may be carried out more easily.
In other embodiments, the signals 32 may be processed in a variety of ways in the implanted unit 24 before transmitting data to the external data device 22 so as to reduce the total amount of data to be transmitted, thereby reducing the power demands of the transmit/receive sub-system 30. Examples include: digitally compressing the signals before transmitting them; selecting only a subset of the detected signals for transmission; selecting a limited segment of time and transmitting signals only from that time segment; extracting salient features of the signals and transmitting data representative of those features rather than the signals themselves. Further processing and analysis of the transmitted data may take place in the external data device 22.
It may be possible to perform some of the processing in the implanted unit 24 and some of the processing in the external data device 22. For example, one or more features from the one or more signals may be extracted with feature extractors in the implanted unit 24. Some or all of the extracted features may be transmitted to the external data device 22 where the features may be classified to predict the onset of a seizure, or the like. If desired, external data device 22 may be customizable to the individual subject. Consequently, the classifier may be adapted to allow for transmission or receipt of only the features from the implanted unit 24 that are predictive for that individual subject. Advantageously, by performing feature extraction in the implanted unit 24 and classification in an external device at least two benefits may be realized. First, the amount of wireless data transmitted from the implanted unit 24 to the external data device 22 is reduced (versus transmitting pre-processed data). Second, classification, which embodies the decision or judgment component, may be easily reprogrammed or custom tailored to the subject without having to reprogram the implanted unit 24.
In yet another embodiment, it may be possible to switch the positions of the classifier and the feature extractors so that feature extraction may be performed external to the body. Pre-processed signals (e.g., filtered, amplified, converted to digital) may be transcutaneously transmitted from implanted unit 24 to the external data device 22 where one or more features are extracted from the one or more signals with feature extractors. Some or all of the extracted features may be transcutaneously transmitted back into the implanted unit 24, where a second stage of processing may be performed on the features, such as classifying of the features (and other signals) to characterize the subject's propensity for the onset of a future seizure. If desired, to improve bandwidth, the classifier may be adapted to allow for transmission or receipt of only the features from the subject communication assembly that are predictive for that individual subject. Advantageously, because feature extractors may be computationally expensive and power hungry, it may be desirable to have the feature extractors external to the body, where it is easier to provide more processing and larger power sources.
The output from the observer algorithm (i.e., brain activity state measurement, “yes” seizure, “no” seizure, normal susceptibility, elevated susceptibility, etc.) may be used by a control assembly 18 of the timing controller 4 to initiate duty cycling, adjust parameters of the duty cycling, and/or determine the parameters of a subsequent neuromodulation signal transmitted to the subject (if any). For example, the control assembly 18 may be adapted to adjust the acquisition epochs and/or stimulation epochs from the acquisition epochs and/or stimulation epochs programmed into the timing controller 4 for the duty cycle.
As noted above, the control assembly 18 can also be adapted to dynamically adjust the stimulation and/or acquisition epochs of the duty cycle. Dynamic adjustments to the timing controller can be accomplished using the closed-loop feedback system described herein. The sensing assembly can acquire a signal from the subject indicative of the subject's brain activity response to a previously delivered stimulation signal. Based on the acquired signal, or parameters thereof, the control assembly can dynamically adjust any of the timing parameters stored in the timing controller, e.g., the duty cycle of the acquisition and/or stimulation epoch.
In alternative embodiments of the present invention, one of the signal processors 42, 56 of the system may include at least one observer algorithm which is configured to be controlled by the timing controller to run and process data acquired by, e.g., an electrode array, at a specified time or times.
In some configurations, the observer algorithm is configured to be controlled by the timing controller 4 to process signal data only at specified times. The times at which such processing occurs can be synchronized with the time at which a sensing electrode array is acquiring a signal from the subject, such that a signal is acquired by the subject and the corresponding signal is received and processed by the observer algorithm to generate an output. The observer algorithm will thus be controlled by the timing controller not to run and process data at specified times. The sensing electrode array can again be synchronized not to acquire any signal from the subject during the time at which the observer algorithm is not running and processing data. Thus, in some embodiments, the sensing electrode array and the observer algorithm can be controlled to be operating at substantially the same time. Controlling when these components are operating and thus receiving power from the system helps control the system's power consumption and can increase the life of the system.
It is further contemplated that one or more of the components of the sensing assembly can also be configured to be controlled by the timing controller 4 to run/operate at specified times. In such embodiments the one or more components can be controlled to run at the same, substantially the same or different times depending on the component. For example, it may be advantageous for the sensing electrode array to acquire a signal from the subject, but rather than analyze the sampled signals immediately, to store the acquired signal in memory module 38, 54 until a later time when the observer algorithm can process the data. For example, a sensing electrode array could be controlled to acquire a signal from a subject based on a specified duty cycle, while the observer algorithm is controlled to process data based on a different duty cycle the sensing electrode.
The control assembly 18 receives an output from the observer algorithm, e.g., a neural state of the subject, seizure prediction, susceptibility to seizure, etc. The control assembly 18 is configured to then determine and/or adjust parameter(s) of the stimulation signal to be delivered to the subject. The stimulation signal to be generated, as determined by the control assembly, is output to the stimulation assembly 8, including the signal generator which generates the stimulation signal. In one embodiment, the control assembly is a state machine, utilizing current and past system behavior in the determination and calculation of a stimulation signal.
The control assembly may calculate waveform parameters of the stimulation signal to be delivered, including, e.g., pulse amplitude, pulse width, pulse frequency, pulses per burst, and burst frequency. Alternatively, the waveform parameters may already be predetermined based on prior physician input. The control assembly can also select between the regulation of pulse voltage or pulse current as the regulated pulse amplitude.
The stimulation assembly 8, shown in
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention For example, while preferred embodiments incorporate a timing controller, alternate embodiments of the present invention may not include a central timing controller, and the stimulation may be designed to always have sufficient inactive epochs between stimulation epochs, and the sensing assembly of the system of the present invention can determine on its own when stimulation artifact is causing a problem and disqualify that portion of the signal, (e.g., the sensing assembly will have the capability to determine when stimulation is not occurring).
It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Number | Name | Date | Kind |
---|---|---|---|
3218638 | Honig | Nov 1965 | A |
3498287 | Ertl | Mar 1970 | A |
3522811 | Schwartz | Aug 1970 | A |
3575162 | Gaarder | Apr 1971 | A |
3837331 | Ross | Sep 1974 | A |
3850161 | Liss | Nov 1974 | A |
3863625 | Viglione et al. | Feb 1975 | A |
3882850 | Bailin et al. | May 1975 | A |
3918461 | Cooper | Nov 1975 | A |
3967616 | Ross | Jul 1976 | A |
3993046 | Fernandez | Nov 1976 | A |
4201224 | John | May 1980 | A |
4214591 | Sato et al. | Jul 1980 | A |
4279258 | John | Jul 1981 | A |
4305402 | Katims | Dec 1981 | A |
4334545 | Shiga | Jun 1982 | A |
4407299 | Culver | Oct 1983 | A |
4408616 | Duffy et al. | Oct 1983 | A |
4421122 | Duffy | Dec 1983 | A |
4471786 | Inagaki | Sep 1984 | A |
4494950 | Fischell | Jan 1985 | A |
4505275 | Chen | Mar 1985 | A |
4545388 | John | Oct 1985 | A |
4556061 | Barreras et al. | Dec 1985 | A |
4566464 | Piccone et al. | Jan 1986 | A |
4573481 | Bullara | Mar 1986 | A |
4579125 | Strobl et al. | Apr 1986 | A |
4590946 | Loeb | May 1986 | A |
4612934 | Borkan | Sep 1986 | A |
4679144 | Cox et al. | Jul 1987 | A |
4686999 | Snyder et al. | Aug 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4735208 | Wyler et al. | Apr 1988 | A |
4768176 | Kehr et al. | Aug 1988 | A |
4768177 | Kehr et al. | Aug 1988 | A |
4785827 | Fischer | Nov 1988 | A |
4793353 | Borkam | Dec 1988 | A |
4817628 | Zealear | Apr 1989 | A |
4838272 | Lieber | Jun 1989 | A |
4844075 | Liss et al. | Jul 1989 | A |
4852573 | Kennedy | Aug 1989 | A |
4867164 | Zabara | Sep 1989 | A |
4873981 | Abrams et al. | Oct 1989 | A |
4878498 | Abrams et al. | Nov 1989 | A |
4903702 | Putz | Feb 1990 | A |
4920979 | Bullara | May 1990 | A |
4926865 | Oman | May 1990 | A |
4955380 | Edell | Sep 1990 | A |
4978680 | Sofia | Dec 1990 | A |
4979511 | Terry | Dec 1990 | A |
4991582 | Byers et al. | Feb 1991 | A |
5010891 | Chamoun | Apr 1991 | A |
5016635 | Graupe | May 1991 | A |
5025807 | Zabara | Jun 1991 | A |
5031618 | Mullett | Jul 1991 | A |
5070873 | Graupe et al. | Dec 1991 | A |
5082861 | Sofia | Jan 1992 | A |
5097835 | Putz | Mar 1992 | A |
RE34015 | Duffy | Aug 1992 | E |
5154172 | Terry | Oct 1992 | A |
5167229 | Peckham et al. | Dec 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5181520 | Wertheim et al. | Jan 1993 | A |
5186170 | Varichio | Feb 1993 | A |
5188104 | Wernicke | Feb 1993 | A |
5190029 | Byron et al. | Mar 1993 | A |
5193539 | Schulman et al. | Mar 1993 | A |
5193540 | Schulman et al. | Mar 1993 | A |
5205285 | Baker, Jr. | Apr 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5215088 | Normann | Jun 1993 | A |
5215089 | Baker, Jr. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
5222503 | Ives | Jun 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5235980 | Varichio et al. | Aug 1993 | A |
5237991 | Baker, Jr. | Aug 1993 | A |
5251634 | Weinberg | Oct 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5265619 | Comby et al. | Nov 1993 | A |
5269302 | Swartz et al. | Dec 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5269315 | Leuchter et al. | Dec 1993 | A |
5292772 | Sofia | Mar 1994 | A |
5293879 | Vonk | Mar 1994 | A |
5299118 | Martens et al. | Mar 1994 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5300094 | Kallok et al. | Apr 1994 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5311876 | Olsen et al. | May 1994 | A |
5312439 | Loeb | May 1994 | A |
5314458 | Najafi et al. | May 1994 | A |
5324316 | Schulman et al. | Jun 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5335657 | Terry et al. | Aug 1994 | A |
5342408 | deColriolis et al. | Aug 1994 | A |
5342409 | Mullett | Aug 1994 | A |
5343064 | Spangler et al. | Aug 1994 | A |
5349962 | Lockard et al. | Sep 1994 | A |
5351394 | Weinberg | Oct 1994 | A |
5361760 | Normann | Nov 1994 | A |
5365939 | Ochs | Nov 1994 | A |
5376359 | Johnson | Dec 1994 | A |
5392788 | Hudspeth | Feb 1995 | A |
5405365 | Hoegnelid et al. | Apr 1995 | A |
5405367 | Schulman et al. | Apr 1995 | A |
5411540 | Edell et al. | May 1995 | A |
5458117 | Chamoun | Oct 1995 | A |
5474547 | Aebischer et al. | Dec 1995 | A |
5476494 | Edell et al. | Dec 1995 | A |
5486999 | Mebane | Jan 1996 | A |
5513649 | Gevins | May 1996 | A |
5531778 | Maschino et al. | Jul 1996 | A |
5540730 | Terry | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5549656 | Reiss | Aug 1996 | A |
5555191 | Hripcsak | Sep 1996 | A |
5571148 | Loeb et al. | Nov 1996 | A |
5571150 | Wernicke | Nov 1996 | A |
5575813 | Edell et al. | Nov 1996 | A |
5578036 | Stone et al. | Nov 1996 | A |
5611350 | John | Mar 1997 | A |
5626145 | Clapp et al. | May 1997 | A |
5626627 | Krystal et al. | May 1997 | A |
5638826 | Wolpaw | Jun 1997 | A |
5649068 | Boser et al. | Jul 1997 | A |
5672154 | Sillen et al. | Sep 1997 | A |
5683422 | Rise | Nov 1997 | A |
5683432 | Goedeke et al. | Nov 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5690691 | Chen et al. | Nov 1997 | A |
5697369 | Long | Dec 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5704352 | Tremblay et al. | Jan 1998 | A |
5707400 | Terry et al. | Jan 1998 | A |
5711316 | Elsberry et al. | Jan 1998 | A |
5713923 | Ward et al. | Feb 1998 | A |
5715821 | Faupel | Feb 1998 | A |
5716377 | Rise et al. | Feb 1998 | A |
5720294 | Skinner | Feb 1998 | A |
5735814 | Elsberry et al. | Apr 1998 | A |
5743860 | Hively et al. | Apr 1998 | A |
5752979 | Benabid | May 1998 | A |
5769778 | Abrams et al. | Jun 1998 | A |
5776434 | Purewal et al. | Jul 1998 | A |
5782798 | Rise | Jul 1998 | A |
5782874 | Loos | Jul 1998 | A |
5782891 | Hassler et al. | Jul 1998 | A |
5792186 | Rise | Aug 1998 | A |
5800474 | Bernabid et al. | Sep 1998 | A |
5813993 | Kaplan | Sep 1998 | A |
5814014 | Elsberry et al. | Sep 1998 | A |
5815413 | Hively et al. | Sep 1998 | A |
5816247 | Maynard | Oct 1998 | A |
5824021 | Rise | Oct 1998 | A |
5832932 | Elsberry et al. | Nov 1998 | A |
5833709 | Rise et al. | Nov 1998 | A |
5857978 | Hively et al. | Jan 1999 | A |
5862803 | Besson et al. | Jan 1999 | A |
5876424 | O'Phelan et al. | Mar 1999 | A |
5899922 | Loos | May 1999 | A |
5913881 | Benz et al. | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5917429 | Otis, Jr. et al. | Jun 1999 | A |
5928272 | Adkins | Jul 1999 | A |
5931791 | Saltzstein et al. | Aug 1999 | A |
5938689 | Fischell et al. | Aug 1999 | A |
5941906 | Barreras et al. | Aug 1999 | A |
5950632 | Reber et al. | Sep 1999 | A |
5957861 | Combs et al. | Sep 1999 | A |
5971594 | Sahai et al. | Oct 1999 | A |
5975085 | Rise | Nov 1999 | A |
5978702 | Ward et al. | Nov 1999 | A |
5978710 | Prutchi et al. | Nov 1999 | A |
5995868 | Dorfmeister et al. | Nov 1999 | A |
6006124 | Fischell et al. | Dec 1999 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6018682 | Rise | Jan 2000 | A |
6042548 | Giuffre | Mar 2000 | A |
6042579 | Elsberry et al. | Mar 2000 | A |
6051017 | Loeb et al. | Apr 2000 | A |
6052619 | John | Apr 2000 | A |
6061593 | Fischell et al. | May 2000 | A |
6066163 | John | May 2000 | A |
6081744 | Loos | Jun 2000 | A |
6094598 | Elsberry et al. | Jul 2000 | A |
6109269 | Rise et al. | Aug 2000 | A |
6117066 | Abrams et al. | Sep 2000 | A |
6128537 | Rise et al. | Oct 2000 | A |
6128538 | Fischell et al. | Oct 2000 | A |
6134474 | Fischell et al. | Oct 2000 | A |
6161045 | Fischell et al. | Dec 2000 | A |
6167304 | Loos | Dec 2000 | A |
6171239 | Humphrey | Jan 2001 | B1 |
6176242 | Rise | Jan 2001 | B1 |
6205359 | Boveja | Mar 2001 | B1 |
6208893 | Hofmann | Mar 2001 | B1 |
6221011 | Bardy | Apr 2001 | B1 |
6227203 | Rise et al. | May 2001 | B1 |
6230049 | Fischell et al. | May 2001 | B1 |
6248126 | Lesser et al. | Jun 2001 | B1 |
6249703 | Stanton | Jun 2001 | B1 |
6263237 | Rise | Jul 2001 | B1 |
6280198 | Calhoun et al. | Aug 2001 | B1 |
6304775 | Iasemidis et al. | Oct 2001 | B1 |
6309406 | Jones et al. | Oct 2001 | B1 |
6328699 | Eigler | Dec 2001 | B1 |
6337997 | Rise | Jan 2002 | B1 |
6339725 | Naritoku | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6343226 | Sunde et al. | Jan 2002 | B1 |
6353754 | Fischell et al. | Mar 2002 | B1 |
6354299 | Fischell et al. | Mar 2002 | B1 |
6356784 | Lozano et al. | Mar 2002 | B1 |
6356788 | Boveja | Mar 2002 | B2 |
6358203 | Bardy | Mar 2002 | B2 |
6358281 | Berrang et al. | Mar 2002 | B1 |
6360122 | Fischell | Mar 2002 | B1 |
6366813 | DiLorenzo | Apr 2002 | B1 |
6366814 | Boveja | Apr 2002 | B1 |
6374140 | Rise | Apr 2002 | B1 |
6386882 | Linberg | May 2002 | B1 |
6402678 | Fischell et al. | Jun 2002 | B1 |
6411854 | Tziviskos et al. | Jun 2002 | B1 |
6427086 | Fischell et al. | Jul 2002 | B1 |
6434419 | Gevins et al. | Aug 2002 | B1 |
6442421 | Quyen et al. | Aug 2002 | B1 |
6443891 | Grevious | Sep 2002 | B1 |
6453198 | Torgerson | Sep 2002 | B1 |
6463328 | John | Oct 2002 | B1 |
6466822 | Pless | Oct 2002 | B1 |
6471645 | Warkentin et al. | Oct 2002 | B1 |
6473639 | Fischell et al. | Oct 2002 | B1 |
6473644 | Terry et al. | Oct 2002 | B1 |
6480743 | Kirkpatrick | Nov 2002 | B1 |
6484132 | Hively et al. | Nov 2002 | B1 |
6488617 | Katz | Dec 2002 | B1 |
6496724 | Levendowski et al. | Dec 2002 | B1 |
6505077 | Kast et al. | Jan 2003 | B1 |
6510340 | Jordan | Jan 2003 | B1 |
6511424 | Moore-Ede | Jan 2003 | B1 |
6529774 | Greene | Mar 2003 | B1 |
6534693 | Fischell et al. | Mar 2003 | B2 |
6547746 | Marino | Apr 2003 | B1 |
6549804 | Osorio et al. | Apr 2003 | B1 |
6553262 | Lang et al. | Apr 2003 | B1 |
6560486 | Osorio et al. | May 2003 | B1 |
6571123 | Ives et al. | May 2003 | B2 |
6571125 | Thompson | May 2003 | B2 |
6572528 | Rohan et al. | Jun 2003 | B2 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6591132 | Gotman et al. | Jul 2003 | B2 |
6591137 | Fischell et al. | Jul 2003 | B1 |
6591138 | Fischell et al. | Jul 2003 | B1 |
6597954 | Fischell et al. | Jul 2003 | B1 |
6600956 | Maschino | Jul 2003 | B2 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6618623 | Pless et al. | Sep 2003 | B1 |
6620415 | Donovan | Sep 2003 | B2 |
6622036 | Suffin | Sep 2003 | B1 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry et al. | Sep 2003 | B2 |
6622047 | Barrett et al. | Sep 2003 | B2 |
6658287 | Litt et al. | Dec 2003 | B1 |
6665562 | Gluckman et al. | Dec 2003 | B2 |
6668191 | Boveja | Dec 2003 | B1 |
6671555 | Gielen | Dec 2003 | B2 |
6678548 | Echauz et al. | Jan 2004 | B1 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6687538 | Hrdlicka et al. | Feb 2004 | B1 |
6735467 | Wilson | May 2004 | B2 |
6760626 | Boveja | Jul 2004 | B1 |
6768969 | Nikitin et al. | Jul 2004 | B1 |
6778854 | Puskas | Aug 2004 | B2 |
6782292 | Whitehurst | Aug 2004 | B2 |
6879859 | Boveja | Apr 2005 | B1 |
6893395 | Kraus et al. | May 2005 | B1 |
6901294 | Whitehurst et al. | May 2005 | B1 |
6901296 | Whitehurst et al. | May 2005 | B1 |
6912419 | Hill | Jun 2005 | B2 |
6921538 | Donovan | Jul 2005 | B2 |
6921541 | Chasin et al. | Jul 2005 | B2 |
6923784 | Stein | Aug 2005 | B2 |
6931274 | Williams | Aug 2005 | B2 |
6934580 | Osorio | Aug 2005 | B1 |
6937891 | Leinders et al. | Aug 2005 | B2 |
6944501 | Pless | Sep 2005 | B1 |
6950706 | Rodriguez | Sep 2005 | B2 |
6973342 | Swanson | Dec 2005 | B1 |
6990372 | Perron et al. | Jan 2006 | B2 |
7010351 | Firlik et al. | Mar 2006 | B2 |
7089059 | Pless | Aug 2006 | B1 |
7117108 | Rapp et al. | Oct 2006 | B2 |
7174212 | Klehn et al. | Feb 2007 | B1 |
7177701 | Pianca | Feb 2007 | B1 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7212851 | Donoghue et al. | May 2007 | B2 |
7231254 | DiLorenzo | Jun 2007 | B2 |
7324851 | DiLorenzo | Jan 2008 | B1 |
7373198 | Bibian et al. | May 2008 | B2 |
7463917 | Martinez | Dec 2008 | B2 |
7631015 | Gupta et al. | Dec 2009 | B2 |
7805196 | Miesel et al. | Sep 2010 | B2 |
7881798 | Miesel et al. | Feb 2011 | B2 |
8055348 | Heruth et al. | Nov 2011 | B2 |
20010051819 | Fischell et al. | Dec 2001 | A1 |
20010056290 | Fischell et al. | Dec 2001 | A1 |
20020002390 | Fischell et al. | Jan 2002 | A1 |
20020035338 | Dear et al. | Mar 2002 | A1 |
20020054694 | Vachtsevanos et al. | May 2002 | A1 |
20020072770 | Pless | Jun 2002 | A1 |
20020072776 | Osorio et al. | Jun 2002 | A1 |
20020072782 | Osorio et al. | Jun 2002 | A1 |
20020077670 | Archer et al. | Jun 2002 | A1 |
20020095099 | Quyen et al. | Jul 2002 | A1 |
20020099412 | Fischell et al. | Jul 2002 | A1 |
20020103512 | Echauz et al. | Aug 2002 | A1 |
20020109621 | Khair et al. | Aug 2002 | A1 |
20020111542 | Warkentin et al. | Aug 2002 | A1 |
20020116042 | Boling | Aug 2002 | A1 |
20020126036 | Flaherty et al. | Sep 2002 | A1 |
20020147388 | Mass et al. | Oct 2002 | A1 |
20020169485 | Pless et al. | Nov 2002 | A1 |
20020177882 | DiLorenzo | Nov 2002 | A1 |
20020188330 | Gielen et al. | Dec 2002 | A1 |
20030004428 | Pless | Jan 2003 | A1 |
20030009207 | Paspa et al. | Jan 2003 | A1 |
20030013981 | Gevins et al. | Jan 2003 | A1 |
20030018367 | DiLorenzo | Jan 2003 | A1 |
20030028072 | Fischell et al. | Feb 2003 | A1 |
20030050549 | Sochor | Mar 2003 | A1 |
20030050730 | Greeven et al. | Mar 2003 | A1 |
20030073917 | Echauz et al. | Apr 2003 | A1 |
20030074033 | Pless et al. | Apr 2003 | A1 |
20030083716 | Nicolelis et al. | May 2003 | A1 |
20030114886 | Gluckman et al. | Jun 2003 | A1 |
20030144709 | Zabara et al. | Jul 2003 | A1 |
20030144711 | Pless et al. | Jul 2003 | A1 |
20030144829 | Geatz et al. | Jul 2003 | A1 |
20030149457 | Tcheng et al. | Aug 2003 | A1 |
20030158587 | Esteller et al. | Aug 2003 | A1 |
20030167078 | Weisner et al. | Sep 2003 | A1 |
20030174554 | Dunstone et al. | Sep 2003 | A1 |
20030176806 | Pineda et al. | Sep 2003 | A1 |
20030181955 | Gielen | Sep 2003 | A1 |
20030187621 | Nikitin et al. | Oct 2003 | A1 |
20030195574 | Osorio et al. | Oct 2003 | A1 |
20030195588 | Fischell et al. | Oct 2003 | A1 |
20030195602 | Boling | Oct 2003 | A1 |
20040034368 | Pless et al. | Feb 2004 | A1 |
20040039427 | Barrett et al. | Feb 2004 | A1 |
20040039981 | Riedl et al. | Feb 2004 | A1 |
20040054297 | Wingeier et al. | Mar 2004 | A1 |
20040059761 | Hively | Mar 2004 | A1 |
20040068199 | Echauz et al. | Apr 2004 | A1 |
20040073273 | Gluckman et al. | Apr 2004 | A1 |
20040077995 | Ferek-Petric | Apr 2004 | A1 |
20040078160 | Frei et al. | Apr 2004 | A1 |
20040082984 | Osorio et al. | Apr 2004 | A1 |
20040087835 | Hively | May 2004 | A1 |
20040097802 | Cohen | May 2004 | A1 |
20040122281 | Fischell et al. | Jun 2004 | A1 |
20040122335 | Sackellares et al. | Jun 2004 | A1 |
20040127810 | Sackellares et al. | Jul 2004 | A1 |
20040133119 | Osorio et al. | Jul 2004 | A1 |
20040133248 | Frei et al. | Jul 2004 | A1 |
20040133390 | Osorio et al. | Jul 2004 | A1 |
20040138516 | Osorio et al. | Jul 2004 | A1 |
20040138517 | Osorio et al. | Jul 2004 | A1 |
20040138536 | Frei et al. | Jul 2004 | A1 |
20040138578 | Pineda et al. | Jul 2004 | A1 |
20040138579 | Deadwyler et al. | Jul 2004 | A1 |
20040138580 | Frei et al. | Jul 2004 | A1 |
20040138581 | Frei et al. | Jul 2004 | A1 |
20040138647 | Osorio et al. | Jul 2004 | A1 |
20040138711 | Osorio et al. | Jul 2004 | A1 |
20040138721 | Osorio et al. | Jul 2004 | A1 |
20040147969 | Mann et al. | Jul 2004 | A1 |
20040152958 | Frei et al. | Aug 2004 | A1 |
20040153129 | Pless et al. | Aug 2004 | A1 |
20040158119 | Osorio et al. | Aug 2004 | A1 |
20040172089 | Whitehurst et al. | Sep 2004 | A1 |
20040176359 | Wermeling | Sep 2004 | A1 |
20040181263 | Balzer et al. | Sep 2004 | A1 |
20040199212 | Fischell | Oct 2004 | A1 |
20040210269 | Shalev et al. | Oct 2004 | A1 |
20040243146 | Chesbrough et al. | Dec 2004 | A1 |
20040267152 | Pineda et al. | Dec 2004 | A1 |
20050004621 | Boveja et al. | Jan 2005 | A1 |
20050010261 | Luders et al. | Jan 2005 | A1 |
20050015128 | Rezai et al. | Jan 2005 | A1 |
20050015129 | Mische | Jan 2005 | A1 |
20050021103 | DiLorenzo | Jan 2005 | A1 |
20050021104 | DiLorenzo | Jan 2005 | A1 |
20050021105 | Firlik et al. | Jan 2005 | A1 |
20050021108 | Klosterman et al. | Jan 2005 | A1 |
20050021313 | Nikitin et al. | Jan 2005 | A1 |
20050027328 | Greenstein | Feb 2005 | A1 |
20050033369 | Badelt | Feb 2005 | A1 |
20050043772 | Stahmann et al. | Feb 2005 | A1 |
20050043774 | Devlin et al. | Feb 2005 | A1 |
20050049649 | Luders et al. | Mar 2005 | A1 |
20050059867 | Cheng | Mar 2005 | A1 |
20050070970 | Knudson et al. | Mar 2005 | A1 |
20050075067 | Lawson et al. | Apr 2005 | A1 |
20050096710 | Kieval | May 2005 | A1 |
20050113885 | Haubrich et al. | May 2005 | A1 |
20050119703 | DiLorenzo | Jun 2005 | A1 |
20050124863 | Cook | Jun 2005 | A1 |
20050131493 | Boveja et al. | Jun 2005 | A1 |
20050137640 | Freeberg et al. | Jun 2005 | A1 |
20050143786 | Boveja | Jun 2005 | A1 |
20050143787 | Boveja et al. | Jun 2005 | A1 |
20050149123 | Lesser et al. | Jul 2005 | A1 |
20050182308 | Bardy | Aug 2005 | A1 |
20050182464 | Schulte et al. | Aug 2005 | A1 |
20050187789 | Hatlestad | Aug 2005 | A1 |
20050197590 | Osorio et al. | Sep 2005 | A1 |
20050203366 | Donoghue et al. | Sep 2005 | A1 |
20050203584 | Twetan et al. | Sep 2005 | A1 |
20050209218 | Meyerson et al. | Sep 2005 | A1 |
20050222503 | Dunlop et al. | Oct 2005 | A1 |
20050222626 | DiLorenzo | Oct 2005 | A1 |
20050222641 | Pless | Oct 2005 | A1 |
20050228249 | Boling | Oct 2005 | A1 |
20050228461 | Osorio et al. | Oct 2005 | A1 |
20050231374 | Diem et al. | Oct 2005 | A1 |
20050234355 | Rowlandson | Oct 2005 | A1 |
20050240245 | Bange et al. | Oct 2005 | A1 |
20050245970 | Erickson et al. | Nov 2005 | A1 |
20050245971 | Brockway et al. | Nov 2005 | A1 |
20050245984 | Singhal et al. | Nov 2005 | A1 |
20050266301 | Smith et al. | Dec 2005 | A1 |
20050277844 | Strother | Dec 2005 | A1 |
20060015034 | Martinerie et al. | Jan 2006 | A1 |
20060015153 | Gliner et al. | Jan 2006 | A1 |
20060094970 | Drew | May 2006 | A1 |
20060111644 | Guttag et al. | May 2006 | A1 |
20060122469 | Martel | Jun 2006 | A1 |
20060129056 | Leuthardt et al. | Jun 2006 | A1 |
20060142822 | Tulgar | Jun 2006 | A1 |
20060173259 | Flaherty et al. | Aug 2006 | A1 |
20060173510 | Besio et al. | Aug 2006 | A1 |
20060200038 | Savit et al. | Sep 2006 | A1 |
20060212092 | Pless et al. | Sep 2006 | A1 |
20060212093 | Pless et al. | Sep 2006 | A1 |
20060212096 | Stevenson | Sep 2006 | A1 |
20060217792 | Hussein et al. | Sep 2006 | A1 |
20060224191 | Dilorenzo | Oct 2006 | A1 |
20060253096 | Blakley et al. | Nov 2006 | A1 |
20060293578 | Rennaker, II | Dec 2006 | A1 |
20060293720 | DiLorenzo et al. | Dec 2006 | A1 |
20070027367 | Oliver et al. | Feb 2007 | A1 |
20070027514 | Gerber | Feb 2007 | A1 |
20070035910 | Stevenson | Feb 2007 | A1 |
20070043459 | Abbott, III et al. | Feb 2007 | A1 |
20070055320 | Weinand | Mar 2007 | A1 |
20070060973 | Ludvig et al. | Mar 2007 | A1 |
20070073355 | DiLorenzo | Mar 2007 | A1 |
20070073357 | Rooney et al. | Mar 2007 | A1 |
20070100398 | Sloan | May 2007 | A1 |
20070142862 | DiLorenzo | Jun 2007 | A1 |
20070149952 | Bland et al. | Jun 2007 | A1 |
20070150024 | Leyde et al. | Jun 2007 | A1 |
20070150025 | DiLorenzo et al. | Jun 2007 | A1 |
20070161919 | DiLorenzo | Jul 2007 | A1 |
20070162086 | DiLorenzo | Jul 2007 | A1 |
20070167991 | DiLorenzo | Jul 2007 | A1 |
20070185890 | VanEpps et al. | Aug 2007 | A1 |
20070213629 | Greene | Sep 2007 | A1 |
20070213785 | Osorio et al. | Sep 2007 | A1 |
20070217121 | Fu et al. | Sep 2007 | A1 |
20070238939 | Giftakis et al. | Oct 2007 | A1 |
20070244407 | Osorio | Oct 2007 | A1 |
20070250077 | Skakoon et al. | Oct 2007 | A1 |
20070250901 | McIntire et al. | Oct 2007 | A1 |
20070287931 | DiLorenzo | Dec 2007 | A1 |
20080021341 | Harris et al. | Jan 2008 | A1 |
20080027347 | Harris et al. | Jan 2008 | A1 |
20080027348 | Harris et al. | Jan 2008 | A1 |
20080027515 | Harris et al. | Jan 2008 | A1 |
20080033502 | Harris et al. | Feb 2008 | A1 |
20080082019 | Ludving et al. | Apr 2008 | A1 |
20080091090 | Guillory et al. | Apr 2008 | A1 |
20080103556 | Li et al. | May 2008 | A1 |
20080161712 | Leyde | Jul 2008 | A1 |
20080161713 | Leyde et al. | Jul 2008 | A1 |
20080221876 | Holdrich | Sep 2008 | A1 |
20080319281 | Aarts | Dec 2008 | A1 |
20090264952 | Jassemidis et al. | Oct 2009 | A1 |
20100023089 | DiLorenzo | Jan 2010 | A1 |
20100125219 | Harris et al. | May 2010 | A1 |
20100145176 | Himes | Jun 2010 | A1 |
20110166430 | Harris et al. | Jul 2011 | A1 |
20110260855 | John et al. | Oct 2011 | A1 |
20110319785 | Snyder et al. | Dec 2011 | A1 |
Number | Date | Country |
---|---|---|
2251852 | Apr 1999 | CA |
2423840 | Feb 2002 | CA |
2428116 | May 2002 | CA |
2428383 | May 2002 | CA |
2425122 | Jun 2002 | CA |
2425004 | Aug 2002 | CA |
2456443 | Jan 2003 | CA |
2491987 | Jan 2004 | CA |
69832022D | Dec 2005 | DE |
0124663 | Nov 1984 | EP |
0898460 | Mar 1999 | EP |
1017313 | Jul 2000 | EP |
1107693 | Jun 2001 | EP |
1145735 | Oct 2001 | EP |
1145736 | Oct 2001 | EP |
1292900 | Mar 2003 | EP |
1307260 | May 2003 | EP |
1331967 | Aug 2003 | EP |
1335668 | Aug 2003 | EP |
1341580 | Sep 2003 | EP |
1404216 | Apr 2004 | EP |
1333753 | Sep 2004 | EP |
1525551 | Apr 2005 | EP |
1558121 | Aug 2005 | EP |
1558128 | Aug 2005 | EP |
1558130 | Aug 2005 | EP |
1558131 | Aug 2005 | EP |
1558132 | Aug 2005 | EP |
1558330 | Aug 2005 | EP |
1558334 | Aug 2005 | EP |
1562674 | Aug 2005 | EP |
0911061 | Oct 2005 | EP |
1609414 | Dec 2005 | EP |
24033673 | Feb 2004 | JP |
1074484 | Feb 1984 | SU |
WO 8501213 | Mar 1985 | WO |
WO 9200119 | Jan 1992 | WO |
WO 9726823 | Jul 1997 | WO |
WO 9734522 | Sep 1997 | WO |
WO 9734524 | Sep 1997 | WO |
WO 9734525 | Sep 1997 | WO |
WO 9739797 | Oct 1997 | WO |
WO 9742990 | Nov 1997 | WO |
WO 9745160 | Dec 1997 | WO |
WO 9849935 | Nov 1998 | WO |
WO 9920342 | Apr 1999 | WO |
WO 9956821 | Nov 1999 | WO |
WO 9956822 | Nov 1999 | WO |
WO 0007494 | Feb 2000 | WO |
WO 0010455 | Mar 2000 | WO |
WO 0141867 | Jun 2001 | WO |
WO 0148676 | Jul 2001 | WO |
WO 0149364 | Jul 2001 | WO |
WO 0167288 | Sep 2001 | WO |
WO 0175660 | Oct 2001 | WO |
WO 0209610 | Feb 2002 | WO |
WO 0209811 | Feb 2002 | WO |
WO 0236003 | May 2002 | WO |
WO 0238031 | May 2002 | WO |
WO 0238217 | May 2002 | WO |
WO 0249500 | Jun 2002 | WO |
WO 02058536 | Aug 2002 | WO |
WO 02067122 | Aug 2002 | WO |
WO 03001996 | Jan 2003 | WO |
WO 03009207 | Jan 2003 | WO |
WO 03030734 | Apr 2003 | WO |
WO 03035165 | May 2003 | WO |
WO 03084605 | Oct 2003 | WO |
WO 2004008373 | Jan 2004 | WO |
WO 2004032720 | Apr 2004 | WO |
WO 2004034231 | Apr 2004 | WO |
WO 2004034879 | Apr 2004 | WO |
WO 2004034880 | Apr 2004 | WO |
WO 2004034881 | Apr 2004 | WO |
WO 2004034882 | Apr 2004 | WO |
WO 2004034883 | Apr 2004 | WO |
WO 2004034885 | Apr 2004 | WO |
WO 2004034982 | Apr 2004 | WO |
WO 2004034997 | Apr 2004 | WO |
WO 2004034998 | Apr 2004 | WO |
WO 2004035130 | Apr 2004 | WO |
WO 2004036370 | Apr 2004 | WO |
WO 2004036372 | Apr 2004 | WO |
WO 2004036376 | Apr 2004 | WO |
WO 2004036377 | Apr 2004 | WO |
WO 2004037342 | May 2004 | WO |
WO 2004043536 | May 2004 | WO |
WO 2004091718 | Oct 2004 | WO |
WO 2005007236 | Jan 2005 | WO |
WO 2005028026 | Mar 2005 | WO |
WO 2005028028 | Mar 2005 | WO |
WO 2005031630 | Apr 2005 | WO |
WO 2005051167 | Jun 2005 | WO |
WO 2005051306 | Jun 2005 | WO |
WO 2005117693 | Dec 2005 | WO |
WO 2006014971 | Feb 2006 | WO |
WO 2006014972 | Feb 2006 | WO |
WO 2006020794 | Feb 2006 | WO |
WO 2006035392 | Apr 2006 | WO |
WO 2007150003 | Dec 2007 | WO |
Number | Date | Country | |
---|---|---|---|
20080114417 A1 | May 2008 | US |